A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Sponsor:

COG

Sponsor Study ID:

AALL1732

CTO #:

103328

NCT Number:

NCT03959085

Phase:

III

Protocol Type:

Treatment

Age Group:

Both

Disease Sites:

Lymphoid Leukemia

Study Objectives:

The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL).

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)